BREAKING NEWS: Aurobindo and Sun Pharma Recall Products From US Markets - medtigo


BREAKING NEWS: Aurobindo and Sun Pharma Recall Products From US Markets

Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp

Aurobindo Pharma and Sun Pharmaceutical Industries, two of India’s largest pharmaceutical companies, are recalling a variety of goods in the US market owing to deviations from acceptable manufacturing practices.

According to the US Food and Drug Administration’s (USFDA) most recent enforcement notice, Aurobindo Pharma’s US-based arm recalls 1,15,776 bottles of Moxifloxacin Ophthalmic Solution, an antibiotic used to treat bacterial infections.

According to the USFDA, Aurobindo Pharma USA Inc, based in Princeton, recalls the concerned batch owing to “failed impurities/degradation requirements.”

On January 14, the business issued a nationwide Class II recall.

The USFDA has issued a recall for 59,232 bottles of chlorthalidone tablets, which are given to decrease excess fluid levels in the body.

Sun Pharma Inc. of New Jersey is recalling the concerned batch due to “foreign substances identified as stainless-steel microscopic wear particles combined with punch lubricating oil and silicone particles from the dust cup,” according to the US Food and Drug Administration.

On February 7, 2022, the business issued a Class II voluntary recall.

According to the USFDA, a Class II recall is launched when the use or exposure to a violative product may produce transitory or medically reversible adverse health effects or when the risk of significant adverse health effects is low.

According to industry estimates, the generic medication market in the United States was anticipated to be worth roughly USD 115.2 billion in 2019.

Leave a Reply